{"pageContent": "Purpose of review: Systemic therapy for patients with hormone-sensitive oligometastatic prostate cancer is non-curative and associated with toxicities. Meanwhile, this population presents unique clinical opportunities to improve outcomes, including the demonstrated benefits of radiotherapy to the primary tumor or oligometastatic sites.", "metaData": {"source": "High expression of QSOX1 is associated with tumor invasiveness and high grades groups in prostate cancer\nhttps://pubmed.ncbi.nlm.nih.gov/29804717/"}}